This article is more than 5 years old. Information may no longer be current.
ESC Congress preview: Anticipated trials, presentations may potentially impact clinical practice
The European Society of Cardiology Congress, which is being held Aug. 31 to Sept. 4 in Paris, will feature late-breaking clinical science presentations that have the potential to have a significant impact on CV care.
The ESC Congress 2019 is expected to bring together 32,000 health care professionals from 150 countries over 5 days of scientific sessions.
This year’s meeting is being held together with the World Congress of Cardiology. The 2019 “Congress Spotlight” is Global Cardiovascular Health, with focus on the management of CVDs around the world, according to meeting organizers.
The meeting will feature six Hot Line sessions, with 27 anticipated trials scheduled for presentation. In addition, there are 13 Late Breaking Science presentations focusing on updates in ACS, aortic valve stenosis, arrhythmias, atrial fibrillation, CV pharmacology. HF, intervention, imaging and digital and prevention.
Some of the highlights include:
- PARAGON HF, which is designed to determine the benefits of angiotensin receptor neprilysin inhibition in patients with HF with preserved ejection fraction. In the trial, 4,800 patients with HFpEF were assigned sacubitril/valsartan (Entresto, Novartis) or valsartan alone.
- GALACTIC, a trial examining the use of goal-directed afterload reduction in patients with acute congestive cardiac decompensation;
- the HOPE 4 trial of a community-based intervention for patients with hypertension in middle-income countries;
- DAPA-HF, a trial of dapagliflozin (Farxiga, AstraZeneca) for the prevention of HF events;
- 2-year data from the MITRA-FR trial, which assessed the effects of percutaneous mitral valve repair for patients with secondary mitral regurgitation;
- main results from the THEMIS trial examining ticagrelor (Brilinta, AstraZeneca) on health outcomes in patients with diabetes and the THEMIS-PCI trial in patients with diabetes, stable CAD and a history of prior PCI;
- new data from the PURE dietary study on the impact of modifiable risk factors and the patterns of CVD and mortality across 21 countries;
- AFIRE, a trial of rivaroxaban (Xarelto, Janssen/Bayer) monotherapy compared with dual therapy in patients with atrial fibrillation and stable CAD; and
- the HiSTORIC trial assessing high-sensitivity troponin to rule out MI at presentation.
Attendees can also learn about updates in Late Breaking Basic and Translational Science, with three sessions dedicated to ACS and HF, hypertension and endothelial dysfunction, and atherosclerosis and aortic stenosis.
Beyond the abstracts and breaking trials, five new 2019 ESC Clinical Practice Guidelines will be released, with new recommendations for diabetes, prediabetes and CVDs developed in collaboration with the European Association for the Study of Diabetes (EASD); acute pulmonary embolism; supraventricular tachycardias; chronic coronary syndromes; and dyslipidemias.
Other sessions will focus on case-based management, technology and innovation pitch presentations, and much more.
See the ESC Congress website to learn more about the scientific program.
Healio and Cardiology Today have you covered during and after the ESC Congress, whether you are attending the meeting in Paris or following from home. Stay tuned to Healio.com/Cardiology for breaking news, expert perspectives, videos and more Follow our live coverage on Twitter at @CardiologyToday and register to receive the news via email here.